Was a SPAC. July 21 was $11<------ LZM Lifezone Metals Limited On sale- $9.13-1.67 (-15.46%)3:54 PM 07/24/23 NYSE | $USD | Post-Market: $9.43 +0.30 (+3.29%) 5:40 PM
It is Tues- NYC where am I. Completely disoriented and hot. Haircut today. Never easy./ Wolfe upgrades Datadog, says engineers cannot live without » 04:57 DDOG Q- What the heck is Datadog?
--Upstart price target raised to $72 from $42 at BTIG » 07:28 UPST --JD.com named as 'Research Tactical Idea' at Morgan Stanley » 07:13 JD
Slow day-- This bio got creamed because they announced financing. But the good news was overlooked they got their product Ok'd-- This should bounce back the sell off is overdone.- Verrica Pharmaceuticals Inc. (VRCA) NasdaqGM - NasdaqGM Real Time Price. 5.11-2.34(-31.46%) At close: July 24 04:00PM EDT 5.55+0.44(+8.61%)<------------- Pre-Market:-
What happened Shares of Verrica Pharmaceuticals(VRCA-31.45%)were down more than 30% as of 2:45 p.m. on Monday. The company, which specializes in dermatology therapeutics, said it was entering into an agreement for as much as $125 million in financing to fund operations. Thehealthcarecompany learned last week that it had received Food and Drug Administration (FDA) approval for a topical therapy to treat a skin infection. NASDAQ: VRCA Verrica Pharmaceuticals Today's Change (-31.45%) -$2.35 Current Price $5.11 VRCA KEY DATA POINTS Market Cap $214M Day's Range $4.75 - $5.76 52wk Range $2.02 - $8.70 Volume 59,454 <------- Low vol sell off Avg Vol 303,192 Gross Margin 89.67% So what Verrica gave the classic good news/bad news combination, but investors were more concerned with the bad news. On Friday, after the markets closed, the company said it had received approval from the FDA for Ycanth (cantharidin) to treat the skin infection molluscum contagiosum in adults and in children 2 or older. According to Verrica, the drug, previously known as VP-102, is the first FDA-approved treatment for a cantharidin-based product to treat the disease, which it said affects roughly 6 million people in the U.S. each year. The FDA approval was based on positive data from two identical phase III clinical trials. The down news, though, was that the company said it had entered into a nonbinding term loan for up to $125 million to help fund operations. Now what The stark move downward seemed a bit much considering the company finally has a marketed product that it expects to launch by September. The loan amount isn't binding and has a term of five years. In the announcement, Verrica said that it plans to borrow $50 million immediately following the close of the transaction, with additional capital available in tranches based on reaching certain revenue milestones. Don't be surprised if the stock bounces back soon.
--Needham upgrades Verrica Pharmaceuticals to Buy on Ycanth opportunity » 07:18 VRCA --Verrica Pharmaceuticals price target raised to $14 from $11 at RBC Capital » 07:14 VRCA Yesterday-> Verrica Pharmaceuticals director buys $1.0M in common stock » 20:16 VRCA
I'M EXPECTING A POST EARN EXPLOSION UP FROM STEM- Stem’s Athena® Receives 2023 Top Product of the Year Award from Environment + Energy Leader SAN FRANCISCO, July 19, 2023--(BUSINESS WIRE)--Stem (NYSE: STEM), a global leader in artificial intelligence (AI)-driven clean energy software and services, today announced that its Athena® platform, has received the Top Product of the Year Award in the Environment + Energy Leader Awards program. The program aims to commend excellence in products and projects that deliver significant energy and environmental benefits. Athena enables organizations to deploy and unlock value from clean energy assets at scale. Athena’s advanced AI and machine learning continuously analyze hundreds of real-time data features from solar, storage, and electric vehicle infrastructure assets against external factors like weather, utility rates, power market prices, and grid constraints. The cloud-native Athena platform is designed to model and predict the optimal real-time operation of each energy asset, and individually control them to store clean energy until it's needed and deliver it when most valuable. Athena AI-automation aims to empower organizations to use more renewable energy, reduce greenhouse gas emissions, lower net energy costs, and participate as a virtual power plant to support the grid. With more than 31 million run-time hours, Athena manages more than 500,000 energy IoT devices and has executed more than 48,000 automated grid dispatches over the past 12 months. "Stem is honored by Environment + Energy Leader’s recognition of Athena’s proven ability to support businesses’ evolving renewable energy needs," said Larsh Johnson, Chief Technology Officer at Stem. "With more than a decade of experience behind us, we understand the complexities of energy management and have designed Athena from the ground up with advanced AI technologies to simplify the clean energy value chain empowering business leaders to confidently deploy and monetize energy technologies while advancing their environmental goals." Sarah Roberts, Co-President of E+E Leader, emphasized the rigorous selection process, stating, "This year’s entrants had to surpass an exceptionally high bar to qualify for an award, thanks to a seasoned and discerning judging panel as well as stringent judging criteria." The outstanding capabilities and achievements of Athena captivated the attention of the program's distinguished panel of judges. One judge remarked, "[Athena] is critical to bringing energy storage, solar PV, EV charging stations, grid systems and other features to its full potential utilization in technology and optimal savings/revenue. [It] is a game changer, in essence is the brain for these technologies." Another judge added, "The analytic sophistication is providing real value for customers and helping to scale renewable and clean technologies." These testimonials affirm the exceptional impact and excellence of Athena in driving sustainability and energy efficiency.
I THINK WE HAVE TO DUMP BARBIE. SHE DRINKS TOO MUCH ANYWAY. Individual Investors Flock to Mattel Stock Individual Investors Flock to Mattel Stock Mon, July 24, 2023, 4:45 PM EDT In this article: MAT +1.84% Individual investors ramped up purchases of Mattel shares in July, as "Barbie" opened Friday with box-office success. They bought more than $12 million worth of Mattel shares on a net basis this month, according to Vanda Research data through Friday.
HUGE NEWS! M. WILSON CAPITULATED-!!! BEAR GOES BACK INTO HIDING... DON'T KNOW HOW TO TAKE THIS..... The chief US equity strategist for Morgan Stanley on Monday conceded that he stuck with the pessimism for too long amid a rebound that has left equity benchmarks within spitting distance of erasing last year’s decline. His forecast for the S&P 500 remains 3,900, a level that has been left behind in the index’s 19% jump to around 4,560. “We were wrong,” Wilson wrote in a note to clients Monday. “2023 has been a story of higher valuations than we expected amid falling inflation and cost cutting.” His team has recently shifted the focus to June 2024, for which the price target is set at 4,200, about 8% below its current level. Wilson has spent most of 2023 warning the rally would reverse itself, sounding alarms on technology shares and arguing that March’s banking turmoil portended a “vicious” selling climax that was needed before shares could start rising again. Seven months in, the benchmark index has mounted a strong rally despite falling profits. A litany of tailwinds, from optimism around artificial intelligence that lifted tech megacaps to a resilient economy where inflation cooled and recession warnings proved premature, has propelled the surge. Wilson is among the majority of Wall Street prognosticators who have missed the equity rally. Some of them are now scrambling to raise their price targets.